More early data manipulation issues tied to Novartis blockbuster as Nature retracts paper
Novartis’ blockbuster gene therapy Zolgensma has proven to be a major success story as a spinal muscular atrophy treatment, helping children who might not otherwise be able to stand or walk due to the rare condition.
But last week, the journal Nature Biotechnology surfaced a new flaw in the therapy’s earliest phase of development, and despite the authors’ objections, the journal retracted an article from February 2010 noting “multiple inaccuracies in the reported mouse lifespans and in the animal inclusions and exclusions.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.